Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Melinta Therapeutics Inc.
DescriptionBroad spectrum multi-drug resistant Gram-negative and Gram-positive antibiotic
Molecular Target Ribosomal 50S subunit
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard Indication Infectious (unspecified)
Indication DetailsTreat extremely drug-resistant infections; Treat multidrug-resistant infections
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today